| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744843 | Clinical Microbiology and Infection | 2018 | 31 Pages |
Abstract
Dalbavancin and oritavancin demonstrate efficacy and safety comparable to standard care in well-designed RCTs and result in cost savings when standard care is treatment that covers MRSA.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
R. Agarwal, S.M. Bartsch, B.J. Kelly, M. Prewitt, Y. Liu, Y. Chen, C.A. Umscheid,